<DOC>
	<DOCNO>NCT00003073</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . PURPOSE : Phase I trial study effectiveness liposomal cytarabine treat young patient recurrent refractory meningeal leukemia , lymphoma , solid tumor .</brief_summary>
	<brief_title>Chemotherapy Treating Young Patients With Recurrent Refractory Meningeal Leukemia , Lymphoma , Solid Tumors</brief_title>
	<detailed_description>OBJECTIVES : I . Determine qualitative quantitative toxic effect tolerability liposomal cytarabine ( Depofoam encapsulate cytarabine ; DTC 101 ) pediatric patient recurrent refractory meningeal malignancy . II . Define safe dose DTC 101 patient future clinical study . III . Determine plasma CSF pharmacokinetics DTC 101 patient . OUTLINE : This dose escalation , multicenter study . Patients place one three age-related stratum : stratum 1 , 3 21 year age ; stratum 2 , least 2 less 3 year age ; stratum 3 , least 1 less 2 year age . Patients receive induction dose intrathecal liposomal cytarabine ( Depofoam encapsulate cytarabine ; DTC 101 ) administer every 2 week 2 course . Patients achieve partial response receive significant clinical benefit stable disease may receive third induction dose DTC 101 , 2 week follow second dose . In absence progressive disease , patient proceed consolidation therapy . During consolidation therapy , intrathecal DTC 101 administer every 4 week 2 course , begin 4 week last induction dose . Patients experience complete significant response proceed maintenance therapy . Patients receive maintenance dose intrathecal DTC 101 every 8 week total 6 dos , begin 4 week second consolidation dose . At least 3 patient evaluate dose level . Dose escalation next level proceeds minimum 3 patient per cohort successfully complete induction therapy evaluate . Patients follow 1 , 2 , 3 , 6 , 9 , 12 month post treatment , relapse death . PROJECTED ACCRUAL : A minimum 12-15 patient accrue stratum 18 24 month .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Nervous System Neoplasms</mesh_term>
	<mesh_term>Central Nervous System Neoplasms</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically proven recurrent refractory leukemia , lymphoma , solid tumor overt meningeal involvement Definition meningeal disease : Leukemia/lymphoma : CSF cell count least 5/mm3 evidence blast cell cytospin preparation cytology Solid tumor : Presence tumor cell cytospin preparation cytology OR evidence meningeal disease CT MRI scan No bone marrow disease PATIENT CHARACTERISTICS : Age : 1 21 Performance Status : ECOG 02 Life Expectancy : At least 8 week Hematopoietic : Platelet count great 40,000/mm3 Hepatic : Bilirubin le 2.0 mg/dL ALT le 5 time upper limit normal Renal : Creatinine le 1.5 mg/dL Other : Not pregnant nursing Negative pregnancy test Effective contraceptive method use fertile patient No uncontrolled illness infection ( except HIV positive patient ) No obstructive hydrocephalus compartmentalization CSF flow PRIOR CONCURRENT THERAPY : Biologic therapy : No acute toxic effect prior immunotherapy No prior allogeneic autologous bone marrow transplantation within 3 month study Chemotherapy : No prior systemic CNS direct chemotherapy within 3 week study No prior nitrosourea within 6 week study No prior intrathecal chemotherapy within 1 week study No acute toxic effect prior chemotherapy No prior DTC 101 Concurrent systemic chemotherapy management primary cancer allow Concurrent dexamethasone systemic chemotherapy regimen allow No concurrent chemotherapy leptomeningeal disease No concurrent high dose methotrexate , high dose cytarabine , mercaptopurine , thiotepa , fluorouracil , topotecan Endocrine therapy : Concurrent prednisone therapy systemic chemotherapy allow Radiotherapy : No prior craniospinal irradiation within 8 week study No acute toxic effect prior radiotherapy Concurrent local radiation therapy allow No concurrent whole brain craniospinal radiotherapy Surgery : Not specify Other : At least 2 week since investigational drug recover No concurrent investigational drug Concurrent antibiotic therapy allow</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>21 Years</maximum_age>
	<verification_date>April 2002</verification_date>
	<keyword>recurrent childhood acute lymphoblastic leukemia</keyword>
	<keyword>recurrent childhood lymphoblastic lymphoma</keyword>
	<keyword>recurrent childhood acute myeloid leukemia</keyword>
	<keyword>childhood diffuse large cell lymphoma</keyword>
	<keyword>childhood immunoblastic large cell lymphoma</keyword>
	<keyword>unspecified childhood solid tumor , protocol specific</keyword>
	<keyword>recurrent/refractory childhood Hodgkin lymphoma</keyword>
	<keyword>leptomeningeal metastasis</keyword>
	<keyword>recurrent childhood small noncleaved cell lymphoma</keyword>
	<keyword>recurrent childhood large cell lymphoma</keyword>
</DOC>